Showing results (1-10 of 65) with videos related to
Sort By:
Pageof 7
Innovations in Pharmacy|May 23, 2022
Pharmacists without Access to the EHR: Practicing with One Hand Tied Behind Our BacksDeeatra S Craddock, Ronald G HallCurrent Pharmaceutical Design|June 27, 2015
Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese WorldRonald G HallInternational Journal of Antimicrobial Agents|July 1, 2004
In vitro activity of parenteral Beta-lactams, levofloxacin and tobramycin alone or in combination against extended-spectrum Beta-lactamase producing Klebsiella pneumoniaeDavid S Burgess, Ronald G HallDiagnostic Microbiology and Infectious Disease|May 12, 2004
In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniaeDavid S Burgess, Ronald G HallInfection and Drug Resistance|May 12, 2015
Profile of tedizolid phosphate and its potential in the treatment of acute bacterial skin and skin structure infectionsRonald G Hall, Heidi N MichaelsThe Annals of Pharmacotherapy|February 15, 2007
Pharmacologic treatment options for nosocomial pneumonia involving methicillin-resistant Staphylococcus aureusDarego O Maclayton, Ronald G HallClinical Therapeutics|September 11, 2007
Simulated comparison of the pharmacodynamics of ciprofloxacin and levofloxacin against Pseudomonas aeruginosa using pharmacokinetic data from healthy volunteers and 2002 minimum inhibitory concentration dataDavid S Burgess, Ronald G HallExpert Review of Anti-Infective Therapy|May 10, 2014
Dosing of antibacterial agents in obese adults: does one size fit all?Kenna D Payne, Ronald G HallExpert Review of Anti-Infective Therapy|December 8, 2015
Dosing of antifungal agents in obese peopleKenna D Payne, Ronald G HallJournal of Clinical Medicine|June 5, 2019
Utilizing the Patient Care Process to Minimize the Risk of Vancomycin-Associated NephrotoxicityAshley R Selby, Ronald G HallPageof 7